Short Interest in Achilles Therapeutics plc (NASDAQ:ACHL) Declines By 79.5%

Achilles Therapeutics plc (NASDAQ:ACHLGet Free Report) was the target of a significant decline in short interest during the month of January. As of January 31st, there was short interest totalling 10,100 shares, a decline of 79.5% from the January 15th total of 49,200 shares. Currently, 0.0% of the shares of the company are sold short. Based on an average daily trading volume, of 287,900 shares, the days-to-cover ratio is currently 0.0 days.

Achilles Therapeutics Stock Performance

NASDAQ:ACHL traded up $0.03 during trading hours on Monday, reaching $0.97. The company had a trading volume of 264,233 shares, compared to its average volume of 505,247. The company has a debt-to-equity ratio of 0.02, a quick ratio of 8.55 and a current ratio of 8.55. The stock has a 50-day moving average of $0.89 and a two-hundred day moving average of $0.89. Achilles Therapeutics has a one year low of $0.74 and a one year high of $1.19.

Achilles Therapeutics (NASDAQ:ACHLGet Free Report) last announced its earnings results on Monday, November 13th. The company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.04). As a group, research analysts predict that Achilles Therapeutics will post -1.52 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in ACHL. Renaissance Technologies LLC raised its holdings in Achilles Therapeutics by 19.6% during the 1st quarter. Renaissance Technologies LLC now owns 30,533 shares of the company’s stock worth $90,000 after purchasing an additional 5,000 shares during the last quarter. Bank of America Corp DE lifted its holdings in Achilles Therapeutics by 130.8% during the first quarter. Bank of America Corp DE now owns 10,450 shares of the company’s stock worth $31,000 after acquiring an additional 5,922 shares in the last quarter. Balyasny Asset Management LLC acquired a new position in shares of Achilles Therapeutics in the 3rd quarter valued at approximately $39,000. Sei Investments Co. bought a new stake in shares of Achilles Therapeutics during the second quarter worth $59,000. Finally, Virtu Financial LLC acquired a new position in Achilles Therapeutics in the 4th quarter worth $28,000. Institutional investors and hedge funds own 48.35% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Bank of America reiterated an “underperform” rating on shares of Achilles Therapeutics in a report on Thursday, December 14th.

Read Our Latest Analysis on Achilles Therapeutics

About Achilles Therapeutics

(Get Free Report)

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma.

Featured Articles

Receive News & Ratings for Achilles Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achilles Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.